Is compounded GLP-1 still legal?
Yes, but far more narrowly than in 2024 — and the FDA moved again this year. What changed, and what to ask.
Updated 2026-09-18 · every price checked by hand
How we make money: one company on this page — Coreage Rx — pays us a commission when a reader signs up through our link. It buys them nothing else: not a better score, not a higher place in the table, not the removal of a single criticism. Our scoring method and full disclosure are both public.
Cheap GLP-1 medication exists because of compounding. So it matters a great deal whether compounding is still allowed, and the answer has changed three times in two years.
Compounded GLP-1s are no longer the freely marketed product they were in 2024. They remain legal in a narrower form, and the rules changed again in 2026.
The timeline
| When | What happened |
|---|---|
| December 2024 | FDA declared the tirzepatide shortage resolved. |
| February 2025 | FDA declared the semaglutide shortage resolved, ending the shortage-based pathway that allowed large-scale compounding. |
| 16 September 2025 | FDA issued more than 55 warning letters to online sellers of compounded GLP-1 medications. |
| 1 April 2026 | FDA reminded compounders that specific conditions must be met for compounded drugs to qualify for exemptions under sections 503A and 503B. |
| 30 April 2026 | FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List, saying there is no clinical need for compounded versions. |
| 30 July 2026 | Comment period on that proposal closed after an extension. |
What it means if you are buying now
- A 503A pharmacy may still compound a GLP-1 for an individual patient when there is a documented, patient-specific clinical reason — for example a required dose or formulation that the approved product does not provide.
- Routinely marketed, off-the-shelf compounded GLP-1 sold like a consumer product is not permitted under that framework.
- If the 503B Bulks List proposal is finalised, outsourcing facilities would lose the pathway they have been using to produce these drugs in volume.
- Compounded versions are not FDA-approved. The agency does not review them for safety, effectiveness or manufacturing quality the way it reviews Zepbound or Wegovy.
The part that matters most. Compounded versions are not FDA-approved. The agency has not reviewed them for safety, effectiveness or manufacturing quality the way it reviewed Zepbound and Wegovy. That is not the same as saying they are unsafe — but it is a genuine difference, and a price comparison that ignores it is not telling you the whole story.
Five questions worth asking any provider
- Which pharmacy fills this, and is it a 503A or 503B facility?
- What is the patient-specific clinical reason for compounding in my case?
- What happens to my prescription — and my prepaid months — if the 503B Bulks List proposal is finalised?
- Can you move me to an FDA-approved product without restarting, and at what price?
- Is the figure I have been quoted the ongoing price or an introductory one?
That third question matters most if you are considering an annual plan. We cover the trade-off in annual versus monthly.
If you would rather avoid the question
Through LillyDirect self-pay, single-dose Zepbound vials at 5 mg, 7.5 mg and 10 mg have been listed at $499/month, with lower starting doses nearer $299-$349. Through NovoCare, Wegovy has been offered at $199/month for the first two fills through 31 December 2026, then $349/month for 0.25-2.4 mg doses. The oral form is listed between $149 and $299/month by dose. Ro works exclusively with approved products, and Mochi and LifeMD will chase insurance coverage for you.